GoodRx (NasdaqGS:GDRX) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAubrey Reynolds - Director of Investor RelationsCameron Harbilas - Equity Research AssociateChris McGinnis - CFOJohn Ransom - Managing DirectorLaura Jensen - Chief Commercial Officer and President of Pharma DirectLisa Gill - Managing DirectorSteven Valiquette - Managing DirectorWendy Barnes - CEOConference Call ParticipantsAllen Lutz - Senior Equity Research AnalystDaniel Grosslight - Senior Research AnalystGeorge ...

Transitioned from a vertically integrated COVID-19 vaccine manufacturer to a lean, R&D-focused licensing organization centered on the Matrix-M adjuvant technology. Secured over $800 million in non-dilutive capital over 18 months through strategic milestones and upfront payments from Sanofi and Pfizer. Leveraged the Pfizer agreement to validate Matrix-M's utility across diverse disease areas, with potential for billions in long-term revenue through milestones and royalties. Optimized the operational ...

Key TakeawaysEli Lilly (LLY) reported that its oral GLP-1, orforglipron, achieved a 9.2% weight loss in Phase 3 trials, significantly outperforming Novo Nordisk's oral semaglutide.Toronto-Dominion Bank (TD) beat Q1 earnings estimates with an adjusted EPS of CAD 2.44, supported by adjusted revenue of CAD 16.63 billion.Danish Prime Minister Mette Frederiksen officially called for a parliamentary election on March 24, citing ongoing conflicts regarding Greenland and new wealth tax proposals.Stellantis (STLA) i ...

Core Viewpoint - Novo Nordisk has been struggling to maintain its competitive edge, with analysts attributing this to management's failure to capitalize on opportunities and sustain momentum against rivals [1]. Company Analysis - Analysts have expressed concerns regarding Novo Nordisk's management decisions, suggesting that the company has lost its competitive advantage in the market [1]. Investment Perspective - The article reflects a long-term investment strategy, emphasizing a balanced portfolio that includes growth, value, and dividend-paying stocks, with a particular focus on value investments [1].

Deutsche Telekom chief executive Timotheus Hoettges expressed dissatisfaction with how the European Union is handling the reform of telecommunication sector rules and called for more deregulation. ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. RBC Capital Initiates Pfizer (PFE) with $25 Target, Warns of Structural Revenue Headwinds Photo by Dan Dennis on Unsplash On February 25, RBC Capital initiated coverage of Pfizer Inc. (NYSE:PFE) with an Underperform rating and a $25 price target. The firm said its outlook reflects an “insurmountable” $15B-$20B revenue decline expected through 2030, with limited visibility into new products that ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Hims & Hers Health, Inc. ("Hims†or the "Company†) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click here to participate. On February 7, 2026, The New York Times reported that the Company would stop selling its version of Wegovy, a popular weight loss drug by competitor Novo Nordisk. A former FDA commissione ...

But beneath the selloff, something unusual has emerged.Novo Nordisk is no longer priced like a hypergrowth AI-era healthcare leader. It's priced like a slow-growth legacy pharma stock.NVO Stock Now Trades At A Fraction Of Peer ValuationsAt just 10.6x earnings, NVO stock trades at a dramatic discount to both obesity-drug rival Eli Lilly and Company and broader pharma peers.CompanyP/E Ratio (TTM)Earnings YieldNovo Nordisk10.6x9.42%Eli Lilly45.4x2.20%Vertex Pharmaceuticals31.8x3.14%Pfizer20.0x5.01%Data Source: ...

MetaVia (NasdaqCM:MTVA) Conference February 25, 2026 10:15 AM ET Company ParticipantsHyung Heon Kim - President and CEOModeratorWelcome back, everyone. We have MetaVia Inc., trades on the Nasdaq under the symbol MTVA. It's a clinical stage biotech company focused on transforming cardiometabolic diseases. It's developing the treatment for obesity and vanogliprl for the treatment of MASH. Happy to welcome the president, H.H. Kim. Welcome back to the conference today. We're very much looking forward to hearing ...

Eli Lilly and Company (NYSE:LLY) is included among the Goldman Sachs Dividend Stocks: Top 14 Stock Picks. Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact On February 24, BofA said Novo Nordisk’s decision to cut GLP-1 list prices may draw attention, but the firm does not expect a meaningful impact on the US market. BofA views the move mainly as an effort to lower copay and coinsurance costs for patients, especially in cases where those costs are tied to the list or WAC pri ...